Related Experiment Video
Updated: May 18, 2026

A Method to Study the C924T Polymorphism of the Thromboxane A2 Receptor Gene
Published on: April 1, 2019
Selected ARHGEF3 Gene Polymorphisms Associated With Platelet Hyperaggregability in Patients With Venous
Stryckova Alena1, Skerenova Maria2, Ivankova Jela1
1National Center of Hemostasis and Thrombosis, Clinic of Hematology and Transfusiology, Comenius University in Bratislava, Jessenius Faculty of Medicine in Martin and University Hospital Martin, Martin, Slovakia.
None:
So called "sticky platelet syndrome" (SPS) is an inherited thrombophilic thrombocytopathy characterized by platelet hyperaggregability to low concentrations of adenosine diphosphate and/or epinephrine using light transmission aggregometry and is a recognized cause of otherwise unexplained venous thromboembolism (VTE). Variants within the ARHGEF3 gene have previously been implicated in platelet-related traits, suggesting its potential role in thrombosis associated with SPS. We investigated the association between eight selected single nucleotide polymorphisms (SNPs) within the ARHGEF3 gene and the risk of VTE in 49 patients with SPS and VTE compared with 70 healthy controls. Genetic associations were evaluated using allelic, genotype-based (dominant and recessive models), and haplotype analyses, with stratification according to SPS subtype. In the overall SPS cohort, the minor allele of rs9851853 was significantly more frequent in patients with SPS and VTE compared to controls. SNP rs4681767 showed a borderline allelic association in the overall cohort but reached statistical significance in patients with SPS type II. Genotype-based analyses revealed significant associations for rs9851853 under the dominant model and for rs4681767 and rs1354034 under the recessive model, predominantly in the SPS type II subgroup. Haplotype analysis identified distinct risk- and protective haplotypes within the ARHGEF3 locus. The TAT haplotype was associated with an increased risk of VTE, whereas the CAC haplotype conferred a protective effect, more significantly in SPS type II patients. Our findings indicate that genetic variability within the ARHGEF3 gene, particularly rs9851853, rs4681767, and rs1354034, may modulate thrombotic susceptibility in patients with SPS, especially in the epinephrine-sensitive SPS type II.
More Related Videos
05:49Procoagulant Platelet Characterization by Measuring Phosphatidylserine Exposure and Microvesicle Release from Human Purified Platelets
Published on: November 29, 2024
11:18Real-time Imaging of Heterotypic Platelet-neutrophil Interactions on the Activated Endothelium During Vascular Inflammation and Thrombus Formation in Live Mice
Published on: April 2, 2013
Related Concept Videos
Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase
Genome-wide Association Studies-GWAS
GWAS does not require the identification of the target gene involved in...
Anticoagulant Drugs: Low-Molecular-Weight Heparins
Pharmacogenomics: Identification of New Drug Targets
Principles of Pharmacogenetics: Types of Genetic Variants